Cargando…

Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure

BACKGROUND: Alzheimer’s Disease (AD) and Fronto temporal lobar dementia (FTLD) are common causes of dementia in the aging population for which limited therapeutical options are available. These disorders are associated with Tau accumulation. We have previously shown that Cerebrolysin(TM) (CBL), a ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Rockenstein, Edward, Ubhi, Kiren, Trejo, Margarita, Mante, Michael, Patrick, Christina, Adame, Anthony, Novak, Philipp, Jech, Marion, Doppler, Edith, Moessler, Herbert, Masliah, Eliezer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122761/
https://www.ncbi.nlm.nih.gov/pubmed/25047000
http://dx.doi.org/10.1186/1471-2202-15-90
_version_ 1782329386763026432
author Rockenstein, Edward
Ubhi, Kiren
Trejo, Margarita
Mante, Michael
Patrick, Christina
Adame, Anthony
Novak, Philipp
Jech, Marion
Doppler, Edith
Moessler, Herbert
Masliah, Eliezer
author_facet Rockenstein, Edward
Ubhi, Kiren
Trejo, Margarita
Mante, Michael
Patrick, Christina
Adame, Anthony
Novak, Philipp
Jech, Marion
Doppler, Edith
Moessler, Herbert
Masliah, Eliezer
author_sort Rockenstein, Edward
collection PubMed
description BACKGROUND: Alzheimer’s Disease (AD) and Fronto temporal lobar dementia (FTLD) are common causes of dementia in the aging population for which limited therapeutical options are available. These disorders are associated with Tau accumulation. We have previously shown that Cerebrolysin(TM) (CBL), a neuropeptide mixture with neurotrophic effects, ameliorates the behavioral deficits and neuropathological alterations in amyloid precursor protein (APP) transgenic (tg) mouse model of AD by reducing hyper-phosphorylated Tau. CBL has been tested in clinical trials for AD, however it’s potential beneficial effects in FTLD are unknown. For this purpose we sought to investigate the effects of CBL in a tg model of tauopathy. Accordingly, double tg mice expressing mutant Tau under the mThy-1 promoter and GSK3β (to enhance Tau phosphorylation) were treated with CBL and evaluated neuropathologically. RESULTS: Compared to single Tau tg mice the Tau/GSK3β double tg model displayed elevated levels of Tau phosphorylation and neurodegeneration in the hippocampus. CBL treatment reduced the levels of Tau phosphorylation in the dentate gyrus and the degeneration of pyramidal neurons in the temporal cortex and hippocampus of the Tau/GSK3β double tg mice. Interestingly, the Tau/GSK3β double tg mice also displayed elevated levels of Dynamin-related protein-1 (Drp-1), a protein that hydrolyzes GTP and is required for mitochondrial division. Ultrastructural analysis of the mitochondria in the Tau/GSK3β double tg mice demonstrated increased numbers and fragmentation of mitochondria in comparison to non-tg mice. CBL treatment normalized levels of Drp-1 and restored mitochondrial structure. CONCLUSIONS: These results suggest that the ability of CBL to ameliorate neurodegenerative pathology in the tauopathy model may involve reducing accumulation of hyper-phosphorylated Tau and reducing alterations in mitochondrial biogenesis associated with Tau.
format Online
Article
Text
id pubmed-4122761
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41227612014-08-07 Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure Rockenstein, Edward Ubhi, Kiren Trejo, Margarita Mante, Michael Patrick, Christina Adame, Anthony Novak, Philipp Jech, Marion Doppler, Edith Moessler, Herbert Masliah, Eliezer BMC Neurosci Research Article BACKGROUND: Alzheimer’s Disease (AD) and Fronto temporal lobar dementia (FTLD) are common causes of dementia in the aging population for which limited therapeutical options are available. These disorders are associated with Tau accumulation. We have previously shown that Cerebrolysin(TM) (CBL), a neuropeptide mixture with neurotrophic effects, ameliorates the behavioral deficits and neuropathological alterations in amyloid precursor protein (APP) transgenic (tg) mouse model of AD by reducing hyper-phosphorylated Tau. CBL has been tested in clinical trials for AD, however it’s potential beneficial effects in FTLD are unknown. For this purpose we sought to investigate the effects of CBL in a tg model of tauopathy. Accordingly, double tg mice expressing mutant Tau under the mThy-1 promoter and GSK3β (to enhance Tau phosphorylation) were treated with CBL and evaluated neuropathologically. RESULTS: Compared to single Tau tg mice the Tau/GSK3β double tg model displayed elevated levels of Tau phosphorylation and neurodegeneration in the hippocampus. CBL treatment reduced the levels of Tau phosphorylation in the dentate gyrus and the degeneration of pyramidal neurons in the temporal cortex and hippocampus of the Tau/GSK3β double tg mice. Interestingly, the Tau/GSK3β double tg mice also displayed elevated levels of Dynamin-related protein-1 (Drp-1), a protein that hydrolyzes GTP and is required for mitochondrial division. Ultrastructural analysis of the mitochondria in the Tau/GSK3β double tg mice demonstrated increased numbers and fragmentation of mitochondria in comparison to non-tg mice. CBL treatment normalized levels of Drp-1 and restored mitochondrial structure. CONCLUSIONS: These results suggest that the ability of CBL to ameliorate neurodegenerative pathology in the tauopathy model may involve reducing accumulation of hyper-phosphorylated Tau and reducing alterations in mitochondrial biogenesis associated with Tau. BioMed Central 2014-07-21 /pmc/articles/PMC4122761/ /pubmed/25047000 http://dx.doi.org/10.1186/1471-2202-15-90 Text en © Rockenstein et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Rockenstein, Edward
Ubhi, Kiren
Trejo, Margarita
Mante, Michael
Patrick, Christina
Adame, Anthony
Novak, Philipp
Jech, Marion
Doppler, Edith
Moessler, Herbert
Masliah, Eliezer
Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure
title Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure
title_full Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure
title_fullStr Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure
title_full_unstemmed Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure
title_short Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure
title_sort cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122761/
https://www.ncbi.nlm.nih.gov/pubmed/25047000
http://dx.doi.org/10.1186/1471-2202-15-90
work_keys_str_mv AT rockensteinedward cerebrolysinefficacyinatransgenicmodeloftauopathyroleinregulationofmitochondrialstructure
AT ubhikiren cerebrolysinefficacyinatransgenicmodeloftauopathyroleinregulationofmitochondrialstructure
AT trejomargarita cerebrolysinefficacyinatransgenicmodeloftauopathyroleinregulationofmitochondrialstructure
AT mantemichael cerebrolysinefficacyinatransgenicmodeloftauopathyroleinregulationofmitochondrialstructure
AT patrickchristina cerebrolysinefficacyinatransgenicmodeloftauopathyroleinregulationofmitochondrialstructure
AT adameanthony cerebrolysinefficacyinatransgenicmodeloftauopathyroleinregulationofmitochondrialstructure
AT novakphilipp cerebrolysinefficacyinatransgenicmodeloftauopathyroleinregulationofmitochondrialstructure
AT jechmarion cerebrolysinefficacyinatransgenicmodeloftauopathyroleinregulationofmitochondrialstructure
AT doppleredith cerebrolysinefficacyinatransgenicmodeloftauopathyroleinregulationofmitochondrialstructure
AT moesslerherbert cerebrolysinefficacyinatransgenicmodeloftauopathyroleinregulationofmitochondrialstructure
AT masliaheliezer cerebrolysinefficacyinatransgenicmodeloftauopathyroleinregulationofmitochondrialstructure